RxDoctor Payments Data

Ghassan Alzayer, MD

Gastroenterology · Washington, DCNPI 1396144804

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 92.5% of the total across 23 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Gilead at 32.3% of the total. Reporting peaked in 2019 at $755 and has fallen 83.5% since, to $124 in 2025. That places this record below the midpoint for gastroenterology clinicians in DC, where the typical reported total is $1,183.

$1,548in general payments, 2019–2025

Across 23 payments — averaging $67.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$500
  • AbbVie$473
  • Pfizer$244
  • Johnson & Johnson$176
  • Boston Scientific$69
  • Pentax Of America, Inc.$67
  • plus $19 from 1 others

What the payments were for

  • Food & beverage$1,43293%
  • Education$1167%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,548 in reported general payments places this provider in the 50th percentile of 77 gastroenterology providers in District of Columbia.

See all gastroenterology providers in District of Columbia

Medicare billing

Part B allowed, 2024
$86,395
Medicare patients
346
Services billed
563

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Omeprazole121$3,395
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl74$1,048
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates17$962
Lansoprazole12$873
Pantoprazole Sodium58$790
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl29$564
Metronidazole12$141

Paid to pharmacies, not to this prescriber.

Other gastroenterology in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →